Nationwide implementation of lenalidomide maintenance in multiple myeloma: A retrospective, real‐world study

Nationwide implementation of lenalidomide maintenance in multiple myeloma: A retrospective, real‐world study

Abstract Lenalidomide maintenance (LM) has shown benefit in progression‐free survival (PFS) and overall survival (OS) in clinical trials. LM is the recommended standard of care in patients with newly diagnosed multiple myeloma (MM) after high‐dose melphalan and autologous stem cell transplantation (...

Full description

Bibliographic Details
Main Authors: Mads Harsløf, Iman Chanchiri, Trine Silkjær, Ulf Christian Frølund, Elena Manuela Teodorescu, Kristina Buchardi Nielsen, Per Ishøy Nielsen, Per Trøllund Pedersen, Katrine Fladeland Iversen, Thomas Lund, Kirsten Grønbæk, Sigrun Thorsteinsdottir, Annette Vangsted, Agoston Gyula Szabo
Format: Article
Language:English
Published: Wiley 2024-04-01
Series:eJHaem
Subjects:
lenalidomide maintenance
multiple myeloma
real‐world evidence
transplant eligible
Online Access:https://doi.org/10.1002/jha2.881

Internet

https://doi.org/10.1002/jha2.881

Similar Items